Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib–midazolam drug-drug interaction study in ALK- or ROS1-positive solid tumors
NL-OMON48899Phase 1Active, not recruiting
- Sponsor
- Takeda
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of brigatinib and midazolam in non-small cell lung cancer (NSCLC) and Nonhematologic neoplasms (2 arms), sponsored by Takeda. Primary endpoints: Midazolam area under the concentration-time curve from time 0 to infinity, Midazolam maximum observed concentration and 1 more. Started Jul 2019; status: active, not recruiting.
02
Drugs
brigatinibmidazolam
03
Conditions
non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON48899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48899.